TY - JOUR

T1 - Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population

T2 - A nationwide register study

AU - Løppenthin, Katrine

AU - Esbensen, Bente Appel

AU - Østergaard, Mikkel

AU - Ibsen, Rikke

AU - Kjellberg, Jakob

AU - Jennum, Poul

PY - 2019/6/19

Y1 - 2019/6/19

N2 - Objective: The aim of this study was to examine the prevalence of morbidity and mortality in patients with seropositive rheumatoid arthritis (RA).Methods: Data were obtained from national population-based registries in the period 1998-2009. Prior to the seropositive RA diagnosis (International Classification of Disorders 10th revision M05), we identified a total of 21,558 patients and 87,384 age- and sex-matched control subjects. Odds for morbidity were calculated before and after the RA diagnosis. We estimated the overall survival based on the Kaplan-Meier method.Results: Patients with RA had statistically significantly higher odds for a number of co-morbidities prior to the onset of RA including diseases of the musculoskeletal system (odds ratio (OR) 3.10, 95% confidence interval (CI) 3.00-3.21), diseases involving the immune system (OR 1.45, 95% CI 1.29-1.64), endocrine diseases (OR 1.09, 95% CI 1.01-1.17), diseases of the circulatory system (OR 1.08, 95% CI 1.03-1.14) and diseases of the respiratory system (OR 1.30, 95% CI 1.22-1.38), compared with age- and sex-matched control subjects. After the RA diagnosis, the same trend was seen with higher odds for the same co-morbidities. We found a 5-year survival of 80% (95% CI 78-81%) for patients with RA, while for control subjects it was 88% (95% CI 88-89%).Conclusion: Compared with age- and sex-matched controls, patients with seropositive RA have higher odds for several co-morbidities prior to and, particularly, after the diagnosis of RA. Furthermore, patients with RA have a lower overall survival compared with age- and sex-matched controls.

AB - Objective: The aim of this study was to examine the prevalence of morbidity and mortality in patients with seropositive rheumatoid arthritis (RA).Methods: Data were obtained from national population-based registries in the period 1998-2009. Prior to the seropositive RA diagnosis (International Classification of Disorders 10th revision M05), we identified a total of 21,558 patients and 87,384 age- and sex-matched control subjects. Odds for morbidity were calculated before and after the RA diagnosis. We estimated the overall survival based on the Kaplan-Meier method.Results: Patients with RA had statistically significantly higher odds for a number of co-morbidities prior to the onset of RA including diseases of the musculoskeletal system (odds ratio (OR) 3.10, 95% confidence interval (CI) 3.00-3.21), diseases involving the immune system (OR 1.45, 95% CI 1.29-1.64), endocrine diseases (OR 1.09, 95% CI 1.01-1.17), diseases of the circulatory system (OR 1.08, 95% CI 1.03-1.14) and diseases of the respiratory system (OR 1.30, 95% CI 1.22-1.38), compared with age- and sex-matched control subjects. After the RA diagnosis, the same trend was seen with higher odds for the same co-morbidities. We found a 5-year survival of 80% (95% CI 78-81%) for patients with RA, while for control subjects it was 88% (95% CI 88-89%).Conclusion: Compared with age- and sex-matched controls, patients with seropositive RA have higher odds for several co-morbidities prior to and, particularly, after the diagnosis of RA. Furthermore, patients with RA have a lower overall survival compared with age- and sex-matched controls.

U2 - 10.1177/2235042X19853484

DO - 10.1177/2235042X19853484

M3 - Journal article

C2 - 31211114

VL - 9

JO - Journal of Comorbidity

JF - Journal of Comorbidity

SN - 2235-042X

ER -